BASF Approaches Evonik With Merger Proposal, FT Says

BASF SE recently made a merger proposal to German rival Evonik Industries AG as part of a push to broaden its geographic and product mix, the Financial Times reported on Sept. 25, 2026.

BASF SE has made a merger proposal to Evonik Industries AG, according to a Financial Times report carried by Bloomberg Industries. The approach is described as part of BASF's effort to widen both its geographic footprint and the mix of products it sells — language that points to a strategic combination rather than an opportunistic grab at a weakened target.

Neither company has published terms, and there is no indication in the report that Evonik's board has accepted, rejected or even formally responded. A proposal is not a deal. But the fact that Germany's largest chemical producer is willing to put a domestic combination of this size on the table says something about where the European chemical industry has arrived.

Why a domestic pairing rather than an overseas one

The stated rationale — expanding geographic and product mix — usually argues for buying assets far from home. Evonik is not far from home. It is a German specialty chemicals group headquartered in the same industrial belt BASF has anchored for more than a century.

That apparent contradiction resolves once you look at what Evonik actually sells. Specialty chemicals are, by construction, higher-margin and less exposed to the commodity cycle than the bulk petrochemicals and intermediates that dominate a Verbund-style integrated site. Evonik's businesses also carry their own customer bases and regional sales networks, particularly in higher-value end markets. Buying them changes BASF's earnings profile even if the acquired plants sit a short drive away. "Geographic mix" in a specialty portfolio often means the mix of end-customers served worldwide, not the address on the factory gate.

There is a defensive reading too. European chemical producers have spent the past several years squeezed between structurally higher energy costs than their US Gulf Coast competitors and Chinese capacity that has kept adding volume into a soft global market. Scale is one of the few levers available domestically: consolidate overlapping overhead, close or repurpose subscale lines, and spread fixed costs across a larger revenue base. That logic has driven portfolio reviews across the sector; a full merger of two national champions is the maximal expression of it.

The antitrust question has more than one regulator in it

A BASF–Evonik combination would not be a routine filing. The European Commission's merger review would be the central gate, and the analysis would be conducted product line by product line rather than at the level of "the chemical industry," which is far too broad a market definition to be meaningful. Where the two companies' catalogues overlap — in particular in additives, catalysts and certain specialty intermediates — the Commission would look at how many credible alternative suppliers a European customer would have left.

The likely shape of any clearance, if it comes, is conditional. Remedy packages in chemicals typically take the form of divestitures of specific product lines or plants to a buyer the regulator considers capable of running them as a going concern. That is a slow process, and it can materially change what the acquirer ends up owning versus what it thought it was buying.

Berlin matters too. Both companies are significant German employers with deep works council structures and, in Evonik's case, a shareholder base with historic ties to the Ruhr region's industrial foundations. Any transaction that implied large-scale site closures would face political resistance independent of the competition analysis. Co-determination is not a formality in German industrial deals; labour representatives sit on supervisory boards and have to be brought along.

What shareholders on both sides will be weighing

Any transaction that implied large-scale site closures would face political resistance independent of the competition analysis.

For Evonik holders, the first question is price and currency: cash, shares, or a mix. A share-based merger hands Evonik investors continuing exposure to a business with far more commodity cyclicality than the one they own now — a trade that some specialty-focused funds will not want to make. A cash offer resolves that but requires BASF to fund it at a point in the cycle when balance-sheet discipline across the sector is under close watch from ratings agencies.

For BASF holders, the question is whether the synergy case survives contact with the integration. Chemical mergers of this scale tend to promise procurement savings, overhead reduction and site rationalisation. They also tend to take years, and the interim period consumes management attention at a moment when the European cost base already demands it.

The broader tape offered no drama on the day of the report. As of the last trade at 15:37 GMT on Sept. 25, 2026, the S&P 500 tracker (SPY) stood at $768.62, up 0.19%, with the Nasdaq 100 proxy (QQQ) at $742.10, up 0.13%, and the Dow tracker (DIA) at $514.68, up 0.39%. That is a quiet, mildly positive US session — the sort of backdrop in which a single European sector story sets the pace for its own group rather than the market.

What to watch from here

A confirmation or denial. Reported approaches frequently draw a short exchange statement from one or both parties. Its wording — whether it acknowledges talks, calls them preliminary, or rejects the proposal as undervaluing the target — will set the next leg.
Evonik's anchor shareholders. A transaction of this type turns on whether the largest holders are sellers at all, and at what valuation. Their posture usually leaks before terms do.
Perimeter signals. If BASF indicates it is interested in parts of Evonik rather than the whole, the deal becomes a carve-out negotiation, with a very different antitrust and financing profile.
Peer read-across. Confirmed consolidation at the top of European chemicals typically pulls forward speculation about mid-cap specialty names as the next targets.
Regulatory signalling. Early commentary from Brussels or the German cartel office about likely market definitions would tell investors how heavy a remedy package to assume.

Until terms exist, this is a disclosed intention rather than a transaction. The more durable takeaway is directional: the largest producer in European chemicals appears to have concluded that the answer to a structurally harder cost environment is to get bigger and to shift its product mix upmarket, and it is willing to look at a domestic rival to do it. Whether Evonik's board agrees, and whether regulators would let the combination stand in anything close to its proposed form, are separate questions with separate timetables.

Key facts

Acquirer: BASF SE, Germany's largest chemical producer
Target: Evonik Industries AG, German specialty chemicals group
Stated rationale: Expanding BASF's geographic and product mix
Market backdrop: S&P 500 tracker SPY at $768.62, +0.19%, as of 15:37 GMT Sept. 25, 2026

Frequently asked questions

What exactly has BASF proposed?

BASF SE recently made a merger proposal to Evonik Industries AG, according to a Financial Times report. The move is described as part of BASF's effort to broaden its geographic and product mix. No financial terms, exchange ratio or structure have been disclosed, and there is no public indication of how Evonik's board has responded.

Has Evonik agreed to anything?

No. The available reporting describes a proposal made by BASF, not an agreed transaction. Merger proposals are routinely made, revised or withdrawn without ever becoming binding agreements. Until either company issues a formal statement or files terms, investors should treat the situation as an approach at a preliminary stage rather than a deal in progress.

Why would BASF want a specialty chemicals business?

Specialty chemicals typically carry higher margins and less exposure to commodity price swings than bulk petrochemicals. Adding a specialty portfolio changes an integrated producer's earnings profile, smoothing cyclicality and bringing different end-customer relationships. That fits BASF's stated aim of widening its product mix and the range of markets it serves globally.

What antitrust hurdles would a merger face?

The European Commission would review the combination product line by product line rather than treating chemicals as one market. Overlaps in additives, catalysts and specialty intermediates would attract the closest scrutiny. Clearance, if granted, would likely require divestitures of specific product lines or plants to buyers regulators consider capable of operating them competitively.

Does German politics affect the outcome?

It can. Both companies are major German employers operating under co-determination rules, meaning labour representatives sit on supervisory boards. Any transaction implying large site closures or job losses would face resistance from works councils and political stakeholders, independent of the competition analysis conducted in Brussels. That pressure often shapes deal structure and timing.

How did broader markets trade on the day of the report?

US benchmarks were modestly higher. As of the last trade at 15:37 GMT on Sept. 25, 2026, the S&P 500 tracker SPY was at $768.62, up 0.19%; the Nasdaq 100 proxy QQQ was at $742.10, up 0.13%; and the Dow tracker DIA was at $514.68, up 0.39%. It was a quiet, mildly positive session overall.

Sources

BASF Made Merger Proposal to German Rival Evonik, FT Reports — Bloomberg Industries